N Yegya-Raman, C M Wright, C J Ladbury, J Chew, S Zhang, S Y Sun, S Burke, J Baron, A J Sim, M J LaRiviere, J C Yang, T J Robinson, Y D Tseng, S A Terezakis, S E Braunstein, S V Dandapani, S Schuster, E A Chong, J P Plastaras, N B Figura
PURPOSE/OBJECTIVE(S): To report an ILROG multi-institutional analysis of bridging radiotherapy (BRT) prior to CD19-targeting chimeric antigen receptor T-cell (CAR T) therapy for relapsed/refractory aggressive B-cell lymphomas (BCL). MATERIALS/METHODS: Weretrospectively reviewed 115 patients (pts) with diffuse large BCL (n = 101, 88%), primary mediastinal BCL (n = 11, 10%), mantle cell lymphoma (n = 2, 2%), and T-cell/histiocyte rich large BCL (n = 1, 1%) who received BRT prior to commercial CAR T from 2018-2020 across 6 institutions...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics